Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
A phase 1/2 trial of Saruparib, Enzalutamide, Abiraterone acetate in prostate cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT05367440 by AstraZeneca, with 174 participants enrolled, started 2022-06-02 and due to reach its primary completion in 2031-04-11. Interventions recorded: AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, Apalutamide. Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Shares Darolutamide, Apalutamide, Enzalutamide, Abiraterone acetate.
- TrialAbiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Shares Apalutamide, Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Shares Saruparib, AstraZeneca, Prostate cancer.
- TrialA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Shares Saruparib, AstraZeneca, Prostate cancer.
- TrialTulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in
Shares Darolutamide, Abiraterone acetate, Prostate cancer.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Apalutamide, Abiraterone acetate, Prostate cancer.
- TrialA Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Shares Saruparib, AstraZeneca, Prostate cancer.